Crescent Capital Partners
Nishil Patel is an Investment Analyst at Crescent Capital Partners, a role held since January 2023, while also serving as a Board Observer at Oceania Glass™ since February 2023. A secondment to National Dental Care occurred from May 2024 to July 2024. Prior experience includes positions as an Analyst at Perpetual Limited and an Investment Banking Summer Analyst at Citi. Nishil's career began with internships at Andover Partners, LoftusLane Capital Partners, Deloitte Australia, and Vidio, along with a role as a Business Advisory Cadet at Boroughs Australia. Nishil holds a Bachelor of Commerce and a Bachelor of Economics with a focus on Finance, Accounting, and Financial Economics from UNSW.
This person is not in any teams
Crescent Capital Partners
Crescent Capital Partners (Crescent) is a Sydney-based private equity firm investing in middle-market companies located in Australia and New Zealand with enterprise values between A$100 million and A$500 million. Crescent was formed in 2000 and has established itself as one of Australasia’s leading middle market private equity firms with its last three funds ranked as top quartile global funds (measured in either USD or AUD), as measured by Cambridge Associates. Crescent’s investment focus is on high-growth companies and sectors, or in industries that are undergoing structural change or that lend themselves to consolidation. Crescent’s role is to accelerate and support the senior management teams of these businesses in reaching their aspirational targets and goals. Crescent has a differentiated investment process that combines thematic and proprietary deal sourcing, with a disciplined and analytical approach to investing and a proactive approach to driving value at portfolio companies. Crescent has particular experience and skills in financial services, healthcare, branded and industrial businesses. In particular, Crescent has been the most active private equity manager in healthcare transactions in Australia measured by number of investments made in the past 10 years. Crescent has had a strong track record in delivering superior returns to investors through successful exits. Crescent is now investing our $1 billion Crescent VII (2023 vintage).